Skip to content
6-K

Foreign Interim / Material

Altamira Therapeutics Ltd. CYTOF

0001213900-24-081199

← back to feed
Filed
Sep 24, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Current Liabilities Q2 2024 · Jun 30, 2024 $1.23M
Current Liabilities Q2 2024 · Dec 31, 2023 $1.06M
Current Liabilities Q2 2024 · Jan 1, 2023 $13.92M
Current Assets Q2 2024 · Jun 30, 2024 $524.01K
Current Assets Q2 2024 · Dec 31, 2023 $1.45M
Current Assets Q2 2024 · Jan 1, 2023 $1.91M
Total Assets Q2 2024 · Jun 30, 2024 $8.07M
Total Assets Q2 2024 · Dec 31, 2023 $9.14M
Total Assets Q2 2024 · Jan 1, 2023 $6.81M
Shares Diluted restated Q2 2024 · Jun 30, 2023 209.96K sh
Cash And Equivalents Q2 2024 · Jun 30, 2023 $55.38K
Cash And Equivalents Q2 2024 · Jan 1, 2023 $16.64K
Cash And Equivalents Q2 2024 · Dec 31, 2022 $16.64K
Eps Diluted Q2 2024 · Jun 30, 2023 −$28.31
Eps Basic Q2 2024 · Jun 30, 2023 −$28.31
Operating Income Q2 2024 · Jun 30, 2023 −$3.66M